@article {BarohnP1.435作者={理查德Barohn和拜伦Gajewski Mamatha Pasnoor莱西布朗和劳拉Herbelin和金姆Kimminau奥马尔Jawdat刘和蒂娜和乍得公园和Pam Shlemon和阿巴斯Dimachkie PAIN-CONTRoLs研究小组},title ={神经病变患者辅助干预:在现实生活中比较治疗情况(PAIN-CONTRoLs) (P1.435)},体积={90}={15}补充数量,elocation-id = {P1.435} ={2018},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={4的目的:确定哪些药物疗法(普瑞巴林度洛西汀、去甲替林、美西律)是最有效的在不明原因引起的神经性疼痛和最佳容忍感觉多神经病(CSPN)。首页背景:CSPN是一种常见的慢性神经病变影响成人和礼物重要的神经性疼痛的多种药物已经尝试包括抗癫痫药,抗抑郁药,外用和毒品。基于web的神经肌肉专家们的一项调查表明普瑞巴林是比其他药物更有效,但是目前没有比较研究评估最有效的药物。设计/方法:我们进行了前瞻性随机开放标签比较有效性研究CSPN的患者通过研究所(PCORI)病人为中心的结果。这项研究使用了一个贝叶斯自适应设计,包括响应自适应随机化。在每个临时分析决定继续招收患者或停止试验成功。CSPN的患者完成了包含和排除标准为进入本研究。病人接受了一个基线神经系统评估和随机分配到4神经性药物治疗12周。co-primary结果是likert-like痛苦规模和戒烟率的变化。结果措施进行基线,第4周、第8周和12。结果:总共有402 CSPN患者134人,126年,73年和69年随机去甲替林、度洛西汀,普瑞巴林和美西律。每个治疗是最好的后验概率分别为0.52,0.43,0.05,和0.00,功效利率25.4 \ % 23.0 \ % 15.1 \ % 20.3 \ \ % %和戒烟率38.1,37.3 \ % 42.5 \ %,分别58.0 \ %。结论:美西律满足我们的标准是一个失败者,主要是由于副作用。 While there was no clear winner, overall nortriptyline and duloxetine outperformed pregabalin and mexiletine.Study Supported by:PCORI: Grant Number: CER-1306-02496Disclosure: Dr. Barohn has nothing to disclose. Dr. Gajewski has nothing to disclose. Dr Pasnoor has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Herbelin has nothing to disclose. Dr. Kimminau has nothing to disclose. Dr. Jawdat has nothing to disclose. Dr. Liu has nothing to disclose. Dr. Parks has nothing to disclose. Dr. Shlemon has nothing to disclose. Dr. Dimachkie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Dimachkie is on the speaker{\textquoteright}s bureau or is a consultant for Baxalta, Catalyst, CSL Behring, Mallinckrodt, Novartis and NuFactor. He has received grants from Alexion, Biomarin, Catalyst, CSL-Behring, FDA/OPD, GSK, MDA, NIH, Novartis, Orphazyme and TM. Dr. Study Team has nothing to disclose.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/90/15_Supplement/P1.435}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }